Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?

Babicki, Mateusz

doi:10.3390/vaccines10101658

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11–14 To the best of our knowledge, at the time of the study relatively very few studies have investigated specifically eligible populations’ reasons for receiving the bivalent second booster dose. 15 , 16 Such knowledge is important and can provide a basis for the development of potential strategies and targeted messaging for increasing vaccine uptake. Therefore, this study aims to fill these knowledge gaps by investigating the reasons for receiving the bivalent second booster dose of the COVID-19 vaccine as well as associated influencing factors among a sample of those who were eligible to be vaccinated in Italy.…”

Section: Introductionmentioning

confidence: 99%

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy

Polla

Giudice

Pelullo

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The Italian Ministry of Health recommended the administration of the bivalent second booster dose of the new available mRNA COVID-19 vaccine for subjects aged 60 y and over, aged 12 y and over with high frailty motivated by concomitant/preexisting conditions, and health-care workers. The purposes of this cross-sectional survey were to investigate the reasons for receiving the bivalent second booster dose of the COVID-19 vaccine and associated influencing factors among the eligible population attending two immunization centers randomly selected in the city of Naples, Italy. A total of 535 subjects participated. Only 17.5% revealed high concern about the possibility of acquiring the COVID-19 disease. Those younger, those who had at least one chronic medical condition, and those who had a higher perceived seriousness of the COVID-19 disease were more likely to be very concerned. Having a higher belief of the vaccine’s safety and usefulness were significant positive predictors of the respondents’ belief of the efficacy of the bivalent second booster dose. The two most common reasons reported for receiving the bivalent second booster dose included the protection for themselves and for their cohabitants. Those younger and those who had a higher perception of the vaccine’s usefulness in preventing SARS-CoV-2 infection were more likely to receive the bivalent second booster dose for the protection of their cohabitants. Health-care organizations and health-care professionals can use these findings in their efforts to design educational and communication interventions to accelerate the uptake of this vaccine for reducing the frequency of this disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy

Polla

Giudice

Pelullo

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

COVID-19 InfoVaccines Platform: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population (Preprint)

Mallah,

Pardo-Seco,

Rivero-Calle

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUND COVID-19 vaccines have saved millions of lives, but COVID-19 vaccine uptake has varied widely across countries, in part due to reluctance among some people to accept the new vaccines as they become available, fuelled in large part by lack of trustworthy information on the vaccines themselves. OBJECTIVE To help health workers provide evidence-based answers to common questions about COVID-19 vaccines and vaccination, and thereby assist individuals in making healthy choices for themselves and their families the WHO Collaborating Centre for Vaccine Safety together with the WHO Regional Office for Europe developed COVID19infovaccines.com, a platform that provides reliable and scientific information under the title: “COVID-19 vaccines and vaccination explained”. METHODS COVID-19 InfoVaccines, a project co-funded by the European Union as part of a joint WHO-EU project to support COVID-19 vaccine rollout and vaccination in 6 Eastern European countries, was launched in February 2021 as a collaborative work of a multidisciplinary team of health-related professionals from different countries representing the WHO Collaborating Centre for Vaccine Safety, the WHO Regional Office for Europe and independent contractors. To increase its reach and visibility, the platform was made available in seven languages, shared on social media networks, and advertised through Facebook in English, Georgian, Russian, Spanish, and Ukrainian. To explore the community adoption of the platform, metadata were drawn from Google Analytics, Google Data Studio, and YouTube Studio. RESULTS 262,592 users accessed COVID-19InfoVaccines.com between February 11, 2021, and January 31st, 2023; with the greatest adoption observed between mid-June and mid-November 2021 (total N=104,041). The content was organized into themes, and the users were most interested in: general questions; vaccine efficacy and duration of protection; vaccine safety; vaccine co-administration, and dose-interval and interchangeability. The lifetime analysis of the platform showed that the number of users varied in function of the epidemiological situation. Moreover, users’ inquiries about a specific topic related to COVID-19 vaccination varied with time and geographic location. 118,510 (45.1%) and 46,644 (17.7%) users scrolled up to 35% and 75% of the COVID-19 InfoVaccines webpage, respectively. The average engagement rate was 71.61% with an average engagement time of 1 minute and 27 seconds. The users accessed the platform from 231 countries and territories, but the majority were located in Ukraine (N=38,404; 14.6%), Spain (N=23,327; 8.9%), and Argentina (N=21,167; 8.1%). Older Facebook users were more interested in COVID-19 information than younger individuals (X2 p-value<0.0001). 228 videos were shared on YouTube. The average Click-Through-Rate (CTR) on Facebook was 7.82%, and that on YouTube was 4.4%, with 60 videos having CTR greater than 5%, falling in the range of average YouTube video CTR (2% - 10%). CONCLUSIONS COVID-19 InfoVaccines, has been a well-used platform to increase awareness about COVID-19 vaccines. Such initiatives are important to ensure that health workers can answer questions that understandably arise with the introduction of new vaccines, and individuals can find evidence-based information when they search online. Easily accessible and reliable information is vital to counter misinformation about vaccines and vaccination, which spreads easily and can negatively impact health-related decisions and thereby individual and public health.

show abstract

Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?

Cited by 2 publications

References 24 publications

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy

COVID-19 InfoVaccines Platform: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population (Preprint)

Contact Info

Product

Resources

About